title: Antitumour effects of streptococcal lipoteichoic acids on Meth A fibrosarcoma.
abstract: The antitumour effects of lipoteichoic acids (LTA) extracted from Streptococcus pyogenes were studied in comparison with other streptococcal cellular components. LTA suppressed the tumour growth of both solid- and ascites-type Meth A fibrosarcoma as did the whole cells of S. pyogenes (OK-432). No other cellular components, such as cell wall peptidoglycan, group-specific C-carbohydrate or type-specific M protein, suppressed the growth of Meth A. LTA, but not the other cellular components, induced tumour necrosis factor (TNF) in Propionibacterium acnes-primed mice. LTA had no direct killing effects on Meth A cells. These results indicate that LTA may be an important antitumour component of OK-432 and that one of the antitumour mechanisms by this streptococcal preparation is the induction of TNF.
authors.affiliation: Applied Research Laboratories, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Usami
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
authors.forename: W
authors.initials: W
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Sugawara
authors.forename: S
authors.initials: S
authors.lastname: Hamada
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Kokeguchi
authors.forename: H
authors.initials: H
authors.lastname: Ohokuni
authors.forename: S
authors.initials: S
authors.lastname: Kotani
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins / Q000627:therapeutic use; D002352:Carrier Proteins; D004305:Dose-Response Relationship, Drug; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000188:drug therapy*; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010457:Peptidoglycan / Q000627:therapeutic use; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use; D013297:Streptococcus pyogenes / Q000378:metabolism; D013682:Teichoic Acids / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000942:Antigens, Bacterial; D000970:Antineoplastic Agents; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D002352:Carrier Proteins; D008070:Lipopolysaccharides; D010457:Peptidoglycan; D011135:Polysaccharides, Bacterial; D013682:Teichoic Acids; D014409:Tumor Necrosis Factor-alpha; C027158:polysaccharide C-substance (Streptococcus); C014689:streptococcal M protein; C009900:lipoteichoic acid